You
are here: Home: CCU 3 | 2003: John
Zalcberg, MB, BS, PhD, FRACP: Select publications
Select publications
Neoadjuvant therapy for the treatment of rectal cancer
Expectancy or primary chemotherapy in patients with
advanced asymptomatic colorectal cancer: A randomized trial. Nordic Gastrointestinal
Tumor Adjuvant Therapy Group. J Clin Oncol 1992;10(6):904-11. Abstract
DeGramont A et al. Oxaliplatin/5-FU/LV
in adjuvant colon cancer: Results of the international randomized MOSAIC
trial. Proc ASCO 2003;Abstract 1015.
Goldberg RM et al. N9741: Oxaliplatin
(Oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11
in advanced colorectal cancer (CRC). Updated efficacy and quality of life (QOL)
data from an intergroup study. Proc ASCO 2003;Abstract 1009.
Hurwitz H et al. Bevacizumab (a monoclonal antibody
to vascular endothelial growth factor) prolongs survival in first-line colorectal
cancer (CRC): Results of a phase III trial of bevacizumab in combination
with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy
in subjects with metastatic CRC. Proc ASCO 2003;Abstract 3646.
Kabbinavar F et al. Phase II, randomized trial comparing
bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients
with metastatic colorectal cancer. J Clin Oncol 2003;21(1):60-5. Abstract.
Maindrault F et al. Time to
disease control (TDC) to evaluate the impact on survival of three chemotherapy
lines in metastatic colorectal cancer (MRC) based on 5-fluorouracil, oxaliplatin
and irinotecan (GERCOR). Proc ASCO 2001;Abstract 581.
Bevacizumab in the treatment of colorectal cancer
Benson AB et al. Bevacizumab
(anti-VEGF) plus FOLFOX4 in previously treated advanced colorectal cancer
(advCRC): An interim toxicity analysis of the Eastern Cooperative Oncology
Group (ECOG) study E3200. Proc ASCO 2003;Abstract 975.
Bergsland EK et al. Bevacizumab (BV) + chemotherapy
(CT) may improve survival in metastatic colorectal cancer (MCRC) subjects
with unfavorable prognostic indicators. Proc ASCO 2001;Abstract 2247.
Berlin JD. Targeting vascular endothelial growth factor
in colorectal cancer. Oncology (Huntingt) 2002;16(8 Suppl 7):13-5. Abstract
Fernando NH, Hurwitz HI. Inhibition of vascular endothelial
growth factor in the treatment of colorectal cancer. Semin Oncol 2003;30(3 Suppl 6):39-50.
Abstract
Giantonio BJ et al. Incorporating angiogenesis inhibition
with bevacizumab (anti-VEGF) into frontline chemotherapy with irinotecan
(CPT-11), fluorouracil and leucovorin (FU/LV) for advanced colorectal cancer
(advCRC): A toxicity analysis of ECOG study E2200. Proc ASCO 2002;Abstract 503.
Gray R et al. The safety of adding angiogenesis inhibition
into treatment for colorectal, breast, and lung cancer: The Eastern Cooperative
Oncology Group’s
(ECOG) experience with bevacizumab (anti- VEGF). Proc ASCO 2003;Abstract 825.
Kabbinavar F et al. Phase II, randomized trial comparing
bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients
with metastatic colorectal cancer. J Clin Oncol 2003;21(1):60-5. Abstract
|
